Document:

ex104.htm

    
       

                                                                                                                                                                                                                                                                                                   
EXHIBIT 10.4

    

     

     

                                                                                    Execution Copy

     

    

     

    BROADPOINT
SECURITIES GROUP, INC.

     

    PREEMPTIVE
RIGHTS AGREEMENT

     

    This
PREEMPTIVE RIGHTS AGREEMENT (the “Agreement”) is made
as of the 27th day of
June, 2008, by and between Broadpoint Securities Group, Inc., a New York
corporation (the “Company”), and MAST
Credit Opportunities I Master Fund Limited (the “Investor”). In
consideration of the premises and mutual covenants contained herein, the parties
hereby agree as follows:

     

    1.    Definitions. For purposes of this
Agreement:

     

    1.1.    The term
“Affiliate” has
the meaning set forth in Rule 12b-2 under the Securities Exchange Act of 1934,
as amended, as in effect as on the date hereof.

     

    1.2.    The term
“Business Day”
means any day other than a Saturday, Sunday or a day on which banking
institutions in the State of New York are authorized by law or executive order
to close.

     

    1.3.    The term
“Capital Stock”
shall mean the Common Stock and the preferred stock, par value $0.01 per share,
of the Company.

    

    1.4.    The term
“Common Stock”
shall mean shares of the Company’s common stock, par value $0.01 per
share.

     

    1.5.    The term
“Current Market
Price” means, as of the date of determination, (a) the average of the
daily Fair Market Value under clause (i) or (ii) of the definition thereof of
the Common Stock during the immediately preceding thirty (30) trading days
ending on such date, and (b) if the Common Stock is not then listed or admitted
to trading on any national securities exchange or quoted in the over-the-counter
market, then the Fair Market Value under clause (iii) of the definition thereof
on such date.

     

    1.6.    The term
“Derivative
Securities” means any securities or rights convertible into, or
exercisable or exchangeable for (in each case, directly or indirectly), Common
Stock, including options and warrants.

     

    1.7.    The term
“Equity
Securities” means Capital Stock and all warrants, options or other rights
to acquire Capital Stock, including any debt security that is convertible into,
or exchangeable for, Capital Stock.

     

    1.8.    The term
“Fair Market
Value” shall mean, as of the date of determination: (i) if the Common
Stock is listed on a national securities exchange or admitted to unlisted
trading privileges on such exchange, the Fair Market Value shall be the last
reported sale price of the Common Stock on such exchange or market system on the
last Business Day prior to the date of the Offer Notice or, if no such sale is
made on such day, the average closing bid and asked price for such day on such
exchange or market system; (ii) if the Common Stock is not listed or admitted to
unlisted trading privileges, the Fair Market Value shall be the mean of the last
reported bid and asked prices reported by Pink Sheets or other similar over the
counter quotation service, on the last Business Day prior to the date of the
Offer Notice; or (iii) if the Common Stock is not so listed or admitted to
unlisted trading privileges and bid and asked prices are not so reported, the
Fair Market Value shall be an amount determined mutually by (x) a majority of
the members of the Board of Directors of the Company, and (y) the
Investor.  If the Board of Directors and the Investor shall fail to
agree within five (5) Business Days, the Fair Market Value shall be an amount
determined, at the Company’s expense, by an independent nationally recognized
investment banking firm chosen by the Board of Directors and reasonably
acceptable to the Investor.  Any determination of the Fair Market
Value by an appraiser shall be based on a valuation of the Company as an
entirety without regard to any discount for minority interests or disparate
voting rights among classes of capital stock.

     

    1.9.    The term
“New
Securities” shall mean Equity Securities of the Company, whether now
authorized or not, or rights, options, or warrants to purchase said Equity
Securities, or securities of any type whatsoever that are, or may become,
convertible into or exchangeable into or exercisable for said Equity Securities
(collectively “New
Securities”).

     

    1.10.    The term
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.

     

    2.    Right of First
Offer.  Subject to the terms and conditions specified in this
Section 2, in
the event the Company proposes to offer or sell any New Securities below the
Current Market Price, the Company shall first make an offering of such New
Securities to the Investor in accordance with the provisions of this Section 2; provided, however, that nothing
in this Section 2 shall prevent the Company from offering or selling any New
Securities to Matlin Patterson provided that the Investor is allowed to
participate in such offering in accordance with Section 2(b) .

     

    (a) The
Company shall deliver a notice, in accordance with the provisions of Section 3.5 hereof,
(the “Offer
Notice”) to the Investor stating (i) its bona fide intention to offer
such New Securities, (ii) the number of such New Securities to be offered,
and (iii) the price and terms, if any, upon which it proposes to offer such
New Securities.

    (b) By
written notification received by the Company, within twenty (20) calendar days
after mailing of the Offer Notice, (i) if Matlin Patterson does not elect to
participate in the offering, the Investor may elect to purchase or obtain, at
the price and on the terms specified in the Offer Notice, all such New
Securities, or (ii) if Matlin Patterson does elect to participate in the
offering, the Investor may elect to purchase up to that portion of such New
Securities which equals the proportion that the Common Stock issued and held, or
issuable (directly or indirectly) upon conversion and/or exercise, as
applicable, of any Derivative Securities then held, by the Investor bears to the
total Common Stock of the Company then outstanding (assuming full conversion
and/or exercise, as applicable, of all Derivative Securities held by
MatlinPatterson and the Investor).

     

    (c) If all
New Securities referred to in the Offer Notice are not elected to be purchased
or obtained, the Company may, during the ninety (90) day period following the
expiration of the period provided in Section 2.1(b)
hereof, offer the remaining unsubscribed portion of such New Securities
(collectively, the “Refused Securities”)
to any person or persons at a price not less than, and upon the same terms and
conditions as, those specified in the Offer Notice.  If the Company
does not enter into an agreement for the sale of the New Securities within such
period, or if such agreement is not consummated within thirty (30) days of the
execution thereof, the right provided hereunder shall be deemed to be revived
and such New Securities shall not be offered unless first reoffered to the
Investor in accordance with this Section
2.1.

     

    (d) The right
of first offer in this Section 2 shall not
be applicable to: (i) Common Stock issued or deemed issued to employees or
directors of, or consultants to, the Company or any of its subsidiaries pursuant
to a plan, agreement, or arrangement approved by the Board of Directors of the
Company; (ii) the issuance of securities pursuant to the conversion or exercise
of convertible or exercisable securities outstanding on the date hereof; (iii)
securities issued in connection with any stock split or stock dividend of the
Company; or (iv) the issuance of securities in connection with a bona fide
business acquisition of or by the Company, whether by merger, consolidation,
sale of assets, sale or exchange of stock or otherwise.

     

    3.    Miscellaneous.

     

    3.1.    Termination.  This
Agreement shall terminate upon the earlier to occur of (i)  a
Liquidation Event, as such term is defined in the Company’s Certificate of
Designations, Relative Rights, Preferences and Limitations of Series B Mandatory
Redeemable Preferred Stock, or (ii) such time the Warrant has expired, been
canceled or exercised in full.

    

    3.2.    Transfers, Successors and
Assigns. The terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the
parties.  Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this
Agreement.

     

    3.3.    Governing
Law.  This Agreement shall be governed by and construed in
accordance with the laws of the State of New York.

     

    3.4.    Counterparts. This
Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same
instrument.  This Agreement may also be executed and delivered by
facsimile signature and in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same
instrument.

     

    3.5.    Notices. All notices
and other communications given or made pursuant to this Agreement shall be in
writing and shall be deemed effectively given:  (a) upon personal
delivery to the party to be notified, (b) when sent by confirmed electronic mail
or facsimile if sent during normal business hours of the recipient, and if not
so confirmed, then on the next business day, (c) five (5) days after having been
sent by registered or certified mail, return receipt requested, postage prepaid,
or (d) one (1) day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of
receipt.  All communications shall be sent to the respective parties
at their address as set forth below:

     

    (i)  All
correspondence to the Company shall be addressed as follows:

     

    Broadpoint Securities Group,
Inc.

        One Penn Plaza, 42nd
Floor

                   
New York, New York 10119

           
Fax:
(212) 273-7100

           
Attention:  General
Counsel

     

    with a copy by fax or messenger or
courier to:

     

    Cahill/Wink LLP

    5 Penn Plaza, 23rd floor

    New York, NY 10001

    Fax: (646) 378-2025

    Attention:  Stephen Wink,
Esq.

    

    (ii) All
correspondence to Mast shall be addressed as follows:

     

    
           
If to Mast before September 15,
2008, at the following address:

       

                    
MAST Credit Opportunities I Master Fund Limited

                    
c/o MAST Capital Management, LLC

                    
535 Boylston Street, Suite 401

                    
Boston, Massachusetts 02116

                    
Attention: John S. Ehlinger

                    
Fax: (617) 247-7985

    

     

                                         
If to Mast after September 15,
2008, at the following address:

     

                                                    MAST
Credit Opportunities I Master Fund Limited

                                                    c/o MAST
Capital Management, LLC

                                                    200
Clarendon Street, 51st
Floor

                                                    Boston,
Massachusetts 02116

                                                    Attention:
John S. Ehlinger

    

                                                    with
a copy by fax or messenger or courier to:

     

    Foley
Hoag LLP

    Bay
Colony Corporate Center

    1000
Winter Street, Suite 4000

    Waltham,
Massachusetts 02451

    Attention:
David A. Broadwin, Esq.

    Fax:
(617) 832-7000

    

    3.6.    Amendments and Waivers.   Any term
of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either
retroactively or prospectively), only with the written consent of the Company
and the Investor. No waivers of or exceptions to any term, condition or
provision of this Agreement, in any one or more instances, shall be deemed to
be, or construed as, a further or continuing waiver of any such term, condition
or provision.

     

    [Remainder
of Page Intentionally Left Blank]

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

     

     

    
 

    IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first
above written.

     

    

     

    Broadpoint
Securities Group, Inc.

    

    

    By: /s/
Robert I. Turner

    Name: 
Robert I. Turner

    Title:   
Chief Financial Officer

     

    

     

    Mast
Credit Opportunities I Master Fund Limited

    

    

    By: /s/
Christopher B. Madison

    Name: 
Christopher B. Madison

    Title:   
Partner

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
        
          Signature
Page to Preemptive Rights AgreementExhibit 10.1

             MARKETING, DISTRIBUTION and LICENSE AGREEMENT

This AGREEMENT, effective September 3rd, 2007, is entered into by
Hydrosystemtechnik GmbH, a German corporation, with its principle place of
business at Gewerbepark 13, D-83052 Bruckmuehl, Germany, (herein called
GRANTOR) and HydroDynex, Inc., a Nevada corporation, with its principal place
of business at 8800 Blue Wolf Street, Las Vegas, NV 89123, (herein called
GRANTEE).

RECITALS:

A.  GRANTOR is engaged in the business of developing, manufacturing, selling
and maintaining water treatment plants, particular according to the
proprietary electrochemical process of Anodic Oxidation (AO- System(R)) in
wide variety of applications throughout the world.

B.  The principal of GRANTOR is Meinolf Schoeberl who is the inventor and the
owner of the Patents and who has provided to Hydrosys the exclusive benefit
for the utilisation of the Patents, proprietary technology and the Know- How.

C.  GRANTOR has developed patented proprietary technology and designed an
innovative water treatment system to be utilized for purifying and treating
water. GRANTOR is in the business of: 1) manufacturing integrated water
treatment systems, 2) developing innovative technology related to water
treatment systems, and 3) designing custom systems for a wide variety of
water treatment applications and purposes ("Products").

D.  GRANTEE was organized to market water treatment systems in North America
and desires to represent GRANTOR initially for selling finished AO Units on
an exclusive basis in all markets of the territory defined below except the
dental market and subject to confirming the market demand for the Products
and meeting certain objectives defined in the Agreement, GRANTEE will have
the right to continue to sell finished AO systems on an exclusive basis and
purchase components from GRANTOR to manufacture AO Units for distribution in
all markets of North America, with the exception of the dental market, on an
exclusive basis.

                                   AGREEMENT

NOW, THEREFORE, in consideration of the terms and conditions contained
herein, the parties agree as follows:

1. BASIS FOR THE AGREEMENT

GRANTOR represents that it is the legal owner of issued patents, of the right
to file Patents, Patents Pending and Improvements, Provisional Patent
Applications, Proprietary Information, Trade Secrets, Technical and
Scientific information and Know-How, all pertaining to several designs of
what is commonly referred to as the Anodic Oxidation Water Treatment System.
GRANTOR is prepared to grant exclusive marketing rights to GRANTEE, subject
to certain terms and conditions.

1.1 GRANTEE wishes to acquire the exclusive marketing rights of the Product
pursuant to two issued US- patents and the issuance of future US- Patents for
the express purpose selling GRANTOR'S products on an exclusively basis in all
markets of North America, excluding the dental market. Subject to reaching
certain goals defined in Exhibit B, GRANTEE will be authorized to continue to
sell GRANTOR'S Products on an exclusive basis for the term of this Agreement
or to initiate manufacturing of the AO- Systems and sell in the Territory on
an exclusive basis.

1.2 GRANTEE does not wish to acquire any right, title and interest in any
U.S. patents or patent applications filed as of the date of this agreement
that relate to the Anodic Oxidation water purification and treatment systems
designed and owned by GRANTOR. GRANTEE initially desires to purchase and
resell completed AO- Systems in North America. At a future date and subject
to meeting certain objectives defined in this AGREEMENT as Exhibit B, GRANTEE
can automatically continue to market the PRODUCTS on an exclusive basis or
purchase components from GRANTEE and manufacture AO Units for selling in
North America on an exclusive basis.

2. DEFINITIONS

As used herein, the following capitalized terms or other capitalized terms
defined elsewhere in this Agreement, will have the meanings ascribed thereto
wherever used in this Agreement:

2.1 "Confidential Information" means any business, marketing, technical,
scientific or other information disclosed by any Party which, at the time of
disclosure, is designated as confidential or proprietary.

2.2 "Effective Date" shall be September 3rd, 2007.

2.3 "Gross Production" means the number of AO Units commercially assembled or
manufactured by the GRANTEE, which utilize components or technology owned by
the GRANTOR and sold to customers of GRANTEE or sold by Distributors of
GRANTEE.

2.4 "Intellectual Property Rights" shall mean all intellectual property
rights, including without limitation, any rights in any invention, patent,
discovery, improvement, know-how, utility model, trade-mark, copyright,
industrial design, trade secrets and all rights of whatsoever nature in
materials processing, Confidential Information, and all intangible rights or
privileges owned by Hydrosystemtechnik, GmbH, whether or not registered, and
shall include all rights in any applications and granted registrations for
any of the foregoing.

2.5 "Know-How" means that special knowledge, skill and experience, as applied
to the design or manufacturing of AO Units that is possessed by the GRANTOR.

2.6 "Product(s)" means the Anodic Oxidation water treatment plant (AO-
System) inclusive supplementary products or any successor products and all
technology required to commercially resell or manufacture from GRANTEE in the
Territory and which are utilized to treat water for any and all applications
except dental applications in the Territory.

2.7 "Licensed Technology" means any and all process or proprietary
technology, engineering and design features or components related to the AO-
System, supplementary products or any other successor products ,which were
developed by the GRANTOR.
2.8 "Territory" shall mean North America and comprise the countries of
Canada, the United States and Mexico.

2.9 "GRANTEE" means HydroDynex, Inc., a corporation domiciled in the state of
Nevada.

2.10 "GRANTOR" means Hydrosystemtechnik, GmbH., a corporation domiciled in
the country of Germany.

2.11 Minimum Annual Sales Volume" means the annual net purchase value of
complete AO- Systems or components, defined in Appendix D, purchased at that
value by GRANTEE from GRANTOR.

2.12 "Net Selling Price" means the net sales value of any complete AO- System
sold by GRANTEE or subcontractors of GRANTEE in the Territory, excluding
taxes, customs, fees, transportation and installation expenses, independent
from whether the unit has been purchased totally from GRANTOR or has been
partially manufacture by GRANTEE.

2.13 "Parties" means Hydrosystemtechnik, GmbH and HydroDynex, Inc.

2.14 "Patent(s)" means Provisional Patent(s) Application(s) or Patent
Application(s) means any Patent(s) granted or Patent Application(s) made by
GRANTOR pursuant thereto, and all divisions, continuations, continuations in
part, reissues, substitutes, and extensions thereof.

2.15 "Private Label" means the exclusive labeling, trade name and/or
trademark for the AO- Systems marketed in the Territory.

2.16 "Product Royalty" means a royalty payment made by the GRANTEE to the
GRANTOR on the products assembled or manufacture and sold by GRANTEE in the
Territory, which utilize the GRANTOR's components or technology.

2.17 "Trademarks" means all registered and unregistered trademarks, service
marks, trade names, business names, brand names, product names and any other
indicators of origin, whether registered or unregistered, belonging to either
Party.

2.18 "The Exclusive License" means the right, to the exclusion of any other
entity including GRANTOR, for GRANTEE within the Territory to:

Purchase and import the Products and component parts of Products from GRANTOR
or an entity approved of by GRANTOR, to market, distribute and sell, the
assembly or manufacture according the defined conditions, for installation,
application and maintenance of the Products in the name of GRANTEE or any
related body corporate.

2.19 "The Non- Exclusive License" means the right, to the non- exclusion of
any other entity including GRANTOR, for GRANTEE within the Territory to:

Purchase and import the Products and component parts of Products from GRANTOR
or an entity approved of by GRANTOR, to market, distribute and sell, the
assembly or manufacture according the defined conditions, for installation,
application and maintenance of the Products in the name of GRANTEE or any
related body corporate.

3. GRANT OF MARKETING RIGHTS

3.1 GRANTOR hereby grants to GRANTEE the right to sell finished units in the
Territory in all markets but the dental market on an exclusive basis for a
period of two years, subject to obtaining independent certification and
verification as outline in the Water Treatment Standard 61, completing ETV
testing by NSF International, Inc., and approval of the United States
Environmental Protection Agency, as defined in Appendix A attached hereto. As
a condition of the granting of this License, the Grantee agrees to undertake
the filing of a joint submission in the name of both the GRANTOR and GRANTEE
with the intention of having the GRANTOR being able to utilize any approval
to enhance its credibility in all markets outside the Territory defined in
this agreement.
At the end of each business year, beginning with calendar year three after
the effective date of this agreement, if the GRANTEE has satisfied the
defined objectives of sales defined in table 1 of Appendix B of this
Agreement, the GRANTEE will have the right to continue to sell finished AO
Units on an exclusive basis in the territory. In the event the objectives
defined in Appendix B are not attained at the end of each business year, this
agreement shall, at the option of the GRANTOR, automatically revert to a non-
exclusive marketing agreement and the GRANTEE will not have the authority to
engage in manufacturing of AO Systems.

In the event GRANTEE has attained an annual minimum sales volume of 500.000
EUR at the end of any year, the GRANTEE will have the right to continue to
sell finished AO Units on an exclusive basis in the territory or to purchase
components from the GRANTOR and assemble or manufacture AO Units for its own
account and to sell in the Territory on an exclusive basis. If the minimum
annual sales volume falls below 500.000 EUR again in the following year, the
right to manufacture will expire automatically in the subsequent year, unless
GRANTOR does not agree to extend the right for any reasonable term by written
notice. It being understood that the decision to initiate manufacturing under
this Agreement must be approved in writing by the GRANTOR and such approval
shall not be unreasonably withheld.

(a)  The Parties agree that any Improvements, design changes, modifications
or developments of the Product, made by GRANTOR shall be available to GRANTEE
in the Territory at no additional cost. In the event GRANTOR makes
application for any new patent, GRANTEE shall have the right, during the term
of this agreement, to use the Patent for $1.00 and other good and valuable
consideration, regarding any newly developed product, process or technology
under this Agreement.

(b) The Parties further agree that any Improvements, design changes,
modifications, discoveries or developments related to the Product made by
GRANTEE, may, at the sole option of the GRANTOR, be patented by the GRANTOR
and may be utilized in the Territory by the GRANTEE, so long as the nature of
this Agreement remains exclusive. In this regard, the agent or employee of
the GRANTEE who is responsible for the improvement, design changes,
modifications, discoveries or developments of the Product agrees to execute
any and all documents required to assign all right, title and interest to
Improvements to the GRANTOR for $1.00 and other good and valuable
consideration. GRANTEE shall promptly inform GRANTOR of any such Improvements
and take all necessary steps to assist the GRANTOR in filing an application
for a new patent or a continuation in part of an existing patent. GRANTOR
shall grant to GRANTEE, for no consideration and pursuant a standard Product
Royalty, a license for Improvements in the Territory. Any Improvements,
design changes, modifications or developments of the Product or Technology by
GRANTEE are construed to be a part of this Agreement and GRANTEE shall be
bound to all terms and conditions contained in this Agreement.

3.2 GRANTOR further grants to GRANTEE, the right to use any registered or
not reregistered Trademark, owned, acquired, developed or filed for by the
GRANTOR, relating to the Product or Technology.

3.3 The rights granted pursuant to Sections 3.00 are subject to meeting the
criteria defined in Exhibit B attached, shall be exclusive in nature, for a
period of Ten (10) years with an option by the GRANTEE to extend for an
additional Ten (10) years, so long as the minimum sales volume is maintained,
as outlined in Exhibit B. GRANTEE does not have the right to grant
Sublicenses during the term of this Agreement without first receiving prior
written approval from the GRANTOR.

3.4 Subject to mutual agreement and meeting the criteria defined in clause
3.1 of this agreement, the GRANTEE has the right to assemble and manufacture
AO systems for exclusive marketing in the Territory. A condition of this
Agreement requires the GRANTEE to purchase all components listed on Appendix
D from the GRANTOR during the term of this Agreement. GRANTOR hereby agrees
to provide components to GRANTEE on terms no less favorable that supplied to
any other third party or other GRANTEE of the GRANTOR.

4. LICENSE FEES AND ROYALTIES

4.1 GRANTEE shall, within 120 days of the  Effective Date, as a one time only
Fee, pay to GRANTOR, Ten Thousand Euros (10,000 EUR), which shall be non-
refundable and credited against the Product Royalty called for under Section
4.2. .

A Second Fee in the amount of Twenty Thousand Euros (20,000 EUR), which shall
be non-refundable and credited against the Product Royalty, will be due to
GRANTOR on the First of June, 2008.

A Third Fee in the amount of Twenty Thousand Euros (20,000 EUR) which shall
be non-refundable and credited against the Product Royalty, will be due to
GRANTOR after the GRANTEE has been certified and approved by the United
States Environmental Protection Agency for selling AO-Systems on a commercial
basis in the United States.

4.2 GRANTEE shall pay to GRANTOR a Product Royalty on the products actually
assembled or manufactured and sold by GRANTEE to any non-affiliated third
party, which utilize the Licensed Technology and components paid for by
customers of the GRANTEE. The Product Royalty shall be Ten Percent (10%) of
the Net Selling Price on all AO water treatment systems assembled or
manufactured by GRANTEE or a subcontract manufacture utilized by the GRANTEE
and paid for by customers of GRANTEE. GRANTEE is not obligated to pay a
royalty on finished units purchased from GRANTOR and resold to customers of
GRANTEE. The Product Royalty will remain due in perpetuity and continue to be
paid beyond the life of any Patents. Payments and accounting are to be made
quarterly, within 30 days of the quarter just ending.

5. NO RIGHT TO PURCHASE PATENTS AT THE TIME OF GRANT

5.1 In the event GRANTOR is granted domestic patents covering the Product or
Licensed Technology, GRANTEE has no right or option to purchase the Patents.
It being understood that so long as this AGREEMENT remains effective, GRANTOR
and GRANTEE agree to assume financial responsibility to pay for all direct
costs related to preparing and prosecution of patent applications on a fifty-
fifty basis, including but not limited to: legal fees, filing fees,
maintenance fees and translation costs. Fees paid by the GRANTEE in
connection with direct costs related to all patent expenses will be credited
toward future royalties due GRANTOR for the sale of AO units assembled or
manufactured by GRANTEE.

6. EXPORTATION

6.1 GRANTEE shall be limited to the selling the Product in the Territory.
GRANTEE shall not export the Product outside the Territory without prior
written consent and authorization by GRANTOR.

7. CONFIDENTIALITY

7.1 GRANTEE, GRANTEE's agent and affiliates and GRANTEE's employees shall not
disclose any Proprietary Information, Trade Secrets, Technical and Scientific
information, Know-How or other Confidential Information expressly or implied
disclosed by GRANTOR to GRANTEE without the expressed written permission of
GRANTOR.

7.2 GRANTEE at the option of the GRANTOR shall sign a separate
Confidentiality Agreement relative to any Proprietary Information, Trade
Secrets, Technical and Scientific information, Know-How or other Confidential
Information disclosed by GRANTOR to GRANTEE.

8. PRIVATE LABELS

8.1 All Product(s) used pursuant to this Agreement, may be used under any
Trademark(s) developed or owned by the GRANTOR or a Trademark developed and
owned by the GRANTEE. In the event that any Trademark utilized by the
GRANTEE, is in conflict with another company operating within the Territory,
any different such Private Label selected by GRANTEE may be used.

8.2 The Private Label of the Product shall comply with the appropriate
regulations of all governmental agencies of the countries within the
Territory.

8.3 As long as this AGREEMENT or any modification or extension thereof
remains in force and effect, GRANTEE shall own each such Private Label or
trademark to be used exclusively by GRANTEE on the Product in the Territory.

9. PAYMENTS and REPORT

9.1 Not later than the last day of each January, April, July and October,
GRANTEE shall furnish to GRANTOR a written statement in such detail as
GRANTOR may reasonably require of all amounts due pursuant to Sections 4.2
for the quarterly periods ended the last days of the preceding March, June,
September and December and shall pay to GRANTOR, all amounts due to GRANTOR.

9.2 Payments provided for in this Agreement, when overdue, shall bear
interest at a rate per annum equal to two percent (2%) in excess of the
"Prime Rate" published by the U.S. Edition of "The Wall Street Journal" at
the time such payment is due, and for the time period until payment is
received by GRANTOR.

9.3 If this Agreement is for any reason terminated before all of the payments
herein provided for have been made, GRANTEE shall immediately submit a
terminal report, and pay to GRANTOR any remaining unpaid balance even though
the due date as above provided has not been reached.

10. REPRESENTATIONS AND DISCLAIMER OF WARRANTIES

10.1 Nothing in this AGREEMENT shall be deemed to be a representation or
warranty by GRANTOR of the validity of any Patents, Provisional Patent
Applications, Patents that may issue, Patent Applications and Improvements.
GRANTOR shall have no liability whatsoever to GRANTEE on account of any
injury, loss or damage of any kind or nature, sustained by, or any damage
assessed or asserted against, or any other liability incurred by or imposed
upon GRANTEE arising out of or in connection with, or resulting from:
(a)  The transport, manufacture, assembly, installation, use, sale or
maintenance of the finished Product or single components of it, or:

(b) Any advertising or other promotional activities with respect to any of
the foregoing.

GRANTEE shall hold GRANTOR, and its partners, agents or employees harmless in
the event GRANTOR, or its officers agents or employees, is held liable.

10.2 GRANTOR shall have the right to file, prosecute and maintain Patent
Applications, Provisional Patents and Improvements that are the property of
GRANTOR and shall have the right to determine whether or not, and where to
file a patent application or to abandon the prosecution of any patent or
patent application.

11. PRODUCTION LIABILITY INSURANCE

11.1 GRANTEE will purchase Product Liability Insurance for a minimum cover of
One Million Dollars ($1,000,000) for personal and material damages and list
GRANTOR as an additional insured party on the policy, at no additional
expense to GRANTOR. In the event the GRANTOR become a co-defendant in any
legal action filed in the Territory, GRANTEE will at its sole expense retain
a legal firm to represent both the GRANTOR and the GRANTEE. GRANTEE assumes
any and all legal costs related to the legal action. GRANTEE will indemnify
the GRANTOR to the fullest extent possible by law and pay all costs related
to any legal action whereby the GRANTOR is named as a co-defendant.

12. TERMINATION

12.1 This Agreement shall terminate in 10 years with an option to prolong for
10 additional years on written request of both, the GRANTOR and the GRANTEE,
upon sixty (60) days in advance to the 3rd of September 2017.

12.2 GRANTEE may terminate this Agreement at any time upon sixty (60) days
written notice in advance to the GRANTOR.

12.3 GRANTOR may at its option terminate this Agreement if GRANTEE:
(a) shall be in default of any obligation hereunder; or
(b) shall be adjudged bankrupt; or
(c) shall become insolvent; or
(d) shall make an assignment for the benefit of creditors; or
(e) shall be placed in the hands of a receiver or a trustee in bankruptcy,
the other party may terminate this Agreement by giving thirty (30) days
notice by Registered Mail to the other party, specifying the basis for
termination. If within thirty (30) days after the receipt of such notice, the
party receiving notice shall remedy the condition that formed the basis for
termination, such notice shall cease to be operative, and this Agreement
shall continue in full force.
(f) does not perform a minimum annual sales volume of 100.000 EUR in each
business year subsequent to the third year after the effective date (that
means commencing the evaluation at the end of year 4).

12.4 The word "termination", used elsewhere in this agreement, is to read,
except where the contrary is specifically indicated, as omitting from their
effect, the following rights and obligations, all of which survive any
termination to the degree necessary to permit their complete fulfillment or
discharge:

(a)  GRANTEE's obligation to supply a terminal report as specified in this
Agreement;
(b)  GRANTOR's right to receive or recover, and GRANTEE's obligation to pay
royalties, including accrued or accruable for payment at the time of any
termination;
(c)  GRANTEE's obligation to maintain records under Section 15.00 of this
Agreement;
(d)  licenses, releases and agreements of non-assertion running in favor of
customers or transferees of GRANTEE in respect to products sold or
transferred by GRANTEE prior to any termination and on which Royalties shall
have been paid as provided in paragraph 4.2 of this Agreement;
(e)  Any cause of action or claim of GRANTOR accrued or to accrue, because of
any breach or default by GRANTEE.
(f)  GRANTEE`s right or obligation to maintain the Product in terms of this
agreement unless GRANTEE informs GRANTOR that it wishes to discontinue the
exercise of such rights.

13. DISPUTES AND ARBITRATION

13.1 INITIAL CONSULTATION AND NEGOTIATION. In the event a dispute between
GRANTOR and GRANTEE rises under the Agreement or a party's performance there
under, the matter shall first be escalated to GRANTORS's President and
GRANTEES's President in an attempt to settle such dispute through
consultation and negotiation in good faith and a spirit of mutual
cooperation.

13.2 ESCALATION. If the Presidents are unable to resolve the dispute, it
shall be referred to a conflict resolution committee comprised of one
representative designated by each party. The initial members of the conflict
resolution committee shall be:

For the GRANTOR:        Meinolf Schoeberl
For the GRANTEE:        Jerod Edington

13.3 CONTINUED PERFORMANCE. Except where prevented from doing so by the
matter in dispute, the parties agree to continue performing their obligations
under this Agreement while any good faith dispute is being resolved unless
and until such obligations are terminated by the termination or expiration of
this Agreement.

13.4 ARBITRATION. Any controversy or dispute arising out of or in connection
with this Agreement, its interpretation, performance, or termination, which
the parties are unable to resolve within a reasonable time after written
notice by one party to the other of the existence of such controversy or
dispute, may be submitted to arbitration by either party and if so submitted
by either party, shall be finally settled by arbitration conducted in
accordance with the rules of conciliation and arbitration of the Chamber of
Commerce in effect on the date hereof. Arbitration will be done by three
arbitrators, one each to be proposed by Hydrosystemtechnik and HydroDynex,
and the third to be proposed by the Chamber of Commerce. Any such arbitration
shall take place in the City of Munich, Germany. Such arbitration shall be
conducted in either German or English language and the arbitrators shall
apply the laws of the Country of Germany.

13.5 The institution of any arbitration proceeding hereunder shall not
relieve GRANTEE of its obligation to make payments accrued hereunder pursuant
to Sections 4.00 hereof to GRANTOR during the continuance of such proceeding.
The decision by the arbitrators shall be binding and conclusive upon the
parties, their successors, and assigns and they shall comply with such
decision in good faith, and each party hereby submits itself to the
jurisdiction of the courts of the place where the arbitration is held, but
only for the entry judgment with respect to the decision of the arbitrators
hereunder. Notwithstanding the foregoing, judgment upon award may be entered
in any court where the arbitration takes place, or any court having
jurisdiction.

14. LITIGATION

14.1 Each party shall notify the other party in writing of any suspected
infringement(s) of any Patent(s) or Patent(s) that may issue, Patent
Applications, Provisional Patent Applications and Improvements and registered
Trademarks in the Territory, and shall inform the other party of any evidence
of such infringement(s).

14.2 GRANTOR shall have the first right to institute suit for infringement(s)
in the Territory. GRANTEE agrees to join as a party plaintiff in any such
lawsuit initiated by GRANTOR, if requested by GRANTOR, with all costs,
attorney fees, and expenses to be paid by GRANTOR. However, if GRANTEE does
not institute suit for infringement(s) within ninety (90) days of receipt of
written notice from GRANTEE of GRANTOR's desire to bring suit for
infringement in its own name and on its own behalf, then GRANTEE may, at its
own expense, bring suit or take any other appropriate action.

14.3 If this Agreement is non-exclusive at the time of infringement(s), the
sole right to institute suit for infringement and to recover damages shall
rest with GRANTOR.

14.4 GRANTEE shall be entitled to any recovery of damages resulting from a
lawsuit brought by it pursuant to paragraph 14.1. GRANTOR shall be entitled
to recovery of damages resulting from any lawsuit brought by GRANTOR to
enforce any patent that may issue pursuant to paragraph 14.1.

14.5 Either party may settle with an infringer without the prior approval of
the other party if such settlement would not affect the rights of the other
party under any existing Patent, Patent that may issue, Patent Applications,
Improvements, Provisional Patent Applications and registered Trademarks.

15. RECORDS

15.1 GRANTEE shall keep accurate records of all operations affecting payments
hereunder, and shall permit GRANTOR or its duly authorized agent to inspect
all such records and to make copies of or extracts from such records during
regular business hours throughout the term of this Agreement and for a
reasonable period of not less than three (3) years thereafter.

16. PATENT MAINTENANCE FEES

16.1 Pursuant to Patent(s) and in the event that patents issue on Patent
Applications and Improvements, described in Section 2, or other patents
subsequently issued related to the Licensed Product and Licensed Technology,
maintenance fees shall be paid by Fifty Percent (50%) by GRANTOR and Fifty
percent (50%) by GRANTEE and all documentation of payments shall be provided
to both Parties. GRANTOR, upon request by GRANTEE, shall provide GRANTEE with
records and schedule of maintenance fee due dates.

17. NON-ASSIGNABILITY

17.1 The parties agree that this agreement imposes personal obligations on
GRANTEE. GRANTEE shall not assign any rights under this Agreement not
specifically transferable by its terms without the written consent of
GRANTOR. GRANTOR may assign their rights hereunder.

18. SEVERABILITY

18.1 The parties agree that if any part, term or provision of this Agreement
shall be found illegal or in conflict with any valid controlling law, the
validity of the remaining provisions shall not be affected thereby.

18.2 In the event the legality of any provision of this agreement is brought
into question because of a decision by a court of competent jurisdiction,
GRANTOR, by written notice to GRANTEE, may revise the provision in question
or may delete it entirely so as to comply with the decision of said court.

19. NON-USE OF GRANTOR'S NAME

19.1 In publicizing anything used under this Agreement, GRANTEE shall not use
the name of GRANTOR or otherwise refer to any organization related to
GRANTOR, except with the written approval of GRANTOR. GRANTEE is authorized
to make public the name of the GRANTOR and describe the contractual
relationship between the GRANTOR and GRANTEE, if GRANTEE becomes a publicly
traded company and the disclosures are a requirement and pursuant to the
requirements of the Securities Act of 1933 and 1934.

20. WAIVER, INTEGRATION, ALTERATION

20.1 The waiver of a breach hereunder may be affected only by a written
notification signed by the waiving party and shall not constitute a waiver of
any other breach.

20.2 A provision of this Agreement may be altered or a missing provision may
be added only by a writing signed by both parties.

21. MARKING

21.1 If the GRANTEE initiates assembly or manufacturing of the AO Systems, it
shall place in a conspicuous location on the Product, a patent notice, in
accordance with the Statutes of U.S. Patent Law. GRANTEE agrees to mark any
Product covered by any Patent(s), with the serial number of each such patent.

22. APPLICABLE LAW

22.1 This Agreement shall be constructed in accordance with the substantive
laws of the country of Germany.

22.2 The language under which this Agreement shall be interpreted, arbitrated
or litigated shall be either English or German.

23. NOTICES UNDER THE AGREEMENT

23.1 For the purpose of all written communications and notices between the
parties, their addresses shall be:

GRANTOR:          Hydrosystemtechnik GmbH
                  Gewerbepark 13
                  D-83052 Bruckmuehl, Germany
                  Attention:  Dr. Meinolf Schoeberl, CEO
GRANTEE:          HydroDynex, Inc.
                  8800 Blue Wolf St.
                  Las Vegas, NV 89123
                  Attention:  Jerod C. Edington, President

or any other addresses of which either party shall notify the other party in
writing.

24. RESPONSIBILITY OF TRAINING, TRANSFER AND ASSISTANCE

   The GRANTEE agrees to provide the necessary funds to cover all costs
associated with the training of GRANTEE's employees, transfer of Know How and
data, as well as any kind of special assistance, whether traveling to the
GRANTOR's place of business, preparation and adaptation of documents and
technology or financing the travel, wages, and associated costs of the
GRANTOR'S employee(s) in coming to the GRANTEE's chosen place of business.

IN WITNESS WHEREOF the parties have caused this Agreement to be executed by
their duly authorized officers and/or agents on the respective dates and at
the respective places hereinafter set forth.

EXECUTED

Executed on behalf of
Hydrosystemtechnik GmbH, HYDROSYS
by the authorised person whose signature appears below pursuant to
Corporations Law

Signed at:  Bruckmuehl                 Date:  03. September 2007

Dr.-Ing. Meinolf Schoeberl
Managing Director

Executed on behalf of
HydroDynex, Inc.
by the authorised person whose signature appears below
pursuant to Corporations Law
Signed at:  Spokane                    Date:  September 3rd, 2007

Jerod Edington
President

                                 APPENDIX A

Below is a description of the procedure to be implemented by HydroDynex with
regard to making application and receiving regulatory approval to
commercially sell AO Water Treatment System in the United States.  NSF
International (NSF) and the U.S. Environmental Protection Agency (EPA)
jointly manage the Environmental Technology Verification (ETV) Drinking Water
Systems (DWS) Center.  NSF International's Drinking Water Treatment Unit
(DWTU) Certification Program will most likely be used.

1. Application

-Vendor submits application package for a commercially-ready product to the
DWS Center with the following:

o Specific Operating and Maintenance Manual for the product,

o Previous test performance data, and

o Patent information.

-NSF International reviews the application and discusses the verification
process with the vendor.

-When vendor agrees to ETV testing and signs a contract, a Product Specific
Test Plan (PSTP) is developed.

2. PSTP Development

-ETV protocols and Technology Specific Test Plans (TSTPs) require laboratory
and/or field testing. When field testing is required, an NSF-qualified FTO
may be selected to perform the field test and develop the PSTP.

-A PSTP is developed by the testing entity.

-NSF and the EPA review the PSTP.

-Once the PSTP is approved, testing begins after a shakedown period and
the vendor agrees to testing.

3. Verification Testing

-ETV protocols and TSTPs require laboratory and/or field testing. When field
testing is required, an NSF-qualified FTO may perform the verification test.

-NSF performs an audit of the verification test.

4. Report Preparation

-A draft verification report is developed by the testing entity.

-NSF and the EPA review the report.

-A technical expert reviews the report.

-The vendor reviews the report.

-Other reviews possible with funding partners.

-The report is reviewed for editorial clarity.

-The testing entity revises report to reflect reviewer comments.

-The EPA performs a final clearance review.

5. Final Verification Report

-The final verification statement (VS) is signed by the EPA and NSF, and the
VS and report are posted on both the EPA and NSF websites.

-An email announcement is sent to the DWS Center mailing list announcing the
new verification report.

-The vendor receives ten copies of the verification report and is able to
post the report on their company's web site.

                                APPENDIX B

To retain the benefit of the "Exclusive Licence", GRANTEE must, in each
subsequent year of the Term, beginning in the third calendar year after the
effective date (which means commencing evaluation at the end of 2009), sell
in the Territory, to customers of GRANTEE, Products to the net purchase value
specified in column 2 of Table 1.

Table 1

             YEAR                        EUR OF SALE THRESHOLDS
             ----                        ----------------------
              2                                 E 30,000
              3                                 E 100,000
              4                                 E 300,000
              5                                 E 500,000
              Thereafter in each year           E 500,000

<PAGE>

                                 APPENDIX C

In order to continue the exclusive nature of this agreement:

1. Hydrodynex will lease or buy an AO System reactor from Hydrosystemtechnik
to be used for U.S. technology verification within one year of the signing of
this agreement.  If verification fails and the technology cannot be
sufficiently substantiated to sell in the United States, the AO reactor will
be returned to Hydrosystemtechnik at Hydrodynex' expense and purchase monies
will be refunded in full.

2. Both verification approval and State certification are required to permit
the legal sale of water purifying technological units in the U.S. Each
individual State certifies the unit(s) independently and licenses the
distribution of water purification units in their particular municipality. In
most States, independent laboratory testing is required on various standards,
technological claims, and industrial applications. States, including
California, recognize the standards set forth by the U.S. Environmental
Protection Agency (USEPA) and the independent laboratory companies it
recognizes, such as NSF International. HydroDynex will engage in the process
of securing verification approval by the USEPA for the AO System through NSF
International or other independent laboratory and reach compliance with
America National Standards Institute (ANSI) Water Treatment Standard 61 and
Environmental Technology Verification (ETV) testing. Verification and
certification of the AO System necessary for commercializing and selling
systems in whole or in part within the United States shall be accomplished
within 18 months.

3. At such time as HydroDynex retains NSF and EPA verification through this
process, it will within 90 days make application to the States of California,
Nevada, Oregon, Washington, Idaho and Arizona for certification and pay the
applicable fees required by each state.

4. HydroDynex will take responsibility to translate the owner's manual,
provided by Hydrosystemtechnik, and all other technical information and
documentation, which is a requirement of NSF to properly install and test the
AO system. HydroDynex will also assume responsibility for translating an
installation manual, engineering schematics, replaceable parts cost and part
numbers, all of which will be required by each state in order to secure
certification

5. HydroDynex agrees to provide the necessary funds to follow the
verification protocol outlined in Appendix A.

6. HydroDynex will demonstrate financial responsibility in the form of a bank
credit line or equity funding of not less than $500,000 to accomplish the
objective outlined above.

7. HydroDynex will sell, deliver and install at least one AO System in the
U.S in the two year exclusive period following verification.

                                 APPENDIX D

   In the event HydroDynex is granted the right to assemble and manufacture
the AO Systems for their own account, HydroDynex agrees that it will utilize
Hydrosystemtechnik GmbH as the sole provider of the following components.

1.  AO- Reactor of each type and size, complete mounted and equipped
2.  AO- Control cabinet inclusive soft ware of each type and size, complete
    mounted and equipped
3.  Different custom made sensors and transmitters

<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}]]